- Home
- FTF vs EDIT Comparison
FTF vs EDIT Comparison
Compare FTF & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTF
- EDIT
- Stock Information
- Founded
- FTF 2003
- EDIT 2013
- Country
- FTF United States
- EDIT United States
- Employees
- FTF N/A
- EDIT N/A
- Industry
- FTF Finance/Investors Services
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FTF Finance
- EDIT Health Care
- Exchange
- FTF Nasdaq
- EDIT Nasdaq
- Market Cap
- FTF 256.6M
- EDIT 269.8M
- IPO Year
- FTF N/A
- EDIT 2016
- Fundamental
- Price
- FTF $6.40
- EDIT $4.22
- Analyst Decision
- FTF
- EDIT Buy
- Analyst Count
- FTF 0
- EDIT 11
- Target Price
- FTF N/A
- EDIT $4.56
- AVG Volume (30 Days)
- FTF 153.9K
- EDIT 2.8M
- Earning Date
- FTF 01-01-0001
- EDIT 11-03-2025
- Dividend Yield
- FTF 11.45%
- EDIT N/A
- EPS Growth
- FTF N/A
- EDIT N/A
- EPS
- FTF N/A
- EDIT N/A
- Revenue
- FTF N/A
- EDIT $38,901,000.00
- Revenue This Year
- FTF N/A
- EDIT N/A
- Revenue Next Year
- FTF N/A
- EDIT N/A
- P/E Ratio
- FTF N/A
- EDIT N/A
- Revenue Growth
- FTF N/A
- EDIT N/A
- 52 Week Low
- FTF $5.76
- EDIT $0.91
- 52 Week High
- FTF $6.56
- EDIT $4.07
- Technical
- Relative Strength Index (RSI)
- FTF 47.48
- EDIT 69.08
- Support Level
- FTF $6.33
- EDIT $3.68
- Resistance Level
- FTF $6.40
- EDIT $4.06
- Average True Range (ATR)
- FTF 0.04
- EDIT 0.28
- MACD
- FTF -0.00
- EDIT 0.07
- Stochastic Oscillator
- FTF 41.67
- EDIT 87.73
About FTF Franklin Limited Duration Income Trust of Beneficial Interest
Franklin Limited Duration Income Trust is a closed-end investment company based in the United States. It conducts its investment to provide high, current income, with a secondary objective of capital appreciation. To align with its investment objective is to invest in a diversified mix of fixed-income securities. Its portfolio is dominated by considerable investments in high-yield corporate bonds while touching upon other avenues such as senior secured floating rate corporate loans, mortgage-backed securities, commercial mortgage-backed securities, asset-backed securities, common stocks, and other short-term investments.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.